An inhibitor that targets a specific mutation in relapsed or refractory acute myeloid leukaemia improves the survival rate of patients, a major conference has been told.
The phase III ADMIRAL trial, led by a team at the Abramson Cancer Center of t...
5 years ago
Researchers investigating acute erythroid leukaemia have identified five sub-groups of the condition that have distinct gene mutations and patient outcomes.
The diagnostic criteria for acute erythroid leukaemia have changed over the decades, and t...
5 years ago
